Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis Through PI3K/Akt–FoxO Pathway Modulation - Takeaways - MDSpire

Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis Through PI3K/Akt–FoxO Pathway Modulation

  • By

  • Sijie Bian

  • Lianhui Zhao

  • Xu Wang

  • Zhangwei Wu

  • Maolin Yang

  • Jianliang Ou

  • Tao Han

  • Faxue Liao

  • Qingkai Xue

  • Xingxing Huo

  • Jun Chang

  • April 27, 2026

  • 0 min

Share

  • 1

    Uridine (UD) supplementation significantly suppresses osteoclast differentiation and resorptive function in vitro and mitigates osteoporosis in vivo.

  • 2

    UD administration improves trabecular microarchitecture and reduces osteoclast burden in ovariectomized mice, indicating its potential as a therapeutic agent.

  • 3

    The study identifies a metabolic interplay between pyrimidine metabolism and osteoclast differentiation, highlighting the role of UD in bone health.

  • 4

    Mechanistically, UD inhibits the PI3K/Akt pathway, promotes FoxO nuclear translocation, and reduces reactive oxygen species accumulation.

  • 5

    This research underscores the importance of targeting nucleotide metabolism, particularly pyrimidine metabolism, in osteoporosis treatment strategies.

Original Source(s)

Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis Through PI3K/Akt–FoxO Pathway Modulation

  • by Sijie Bian, Lianhui Zhao, Xu Wang, Zhangwei Wu, Maolin Yang, Jianliang Ou, Tao Han, Faxue Liao, Qingkai Xue, Xingxing Huo, Jun Chang

  • April 27, 2026

Related Content

Current Insights into Osteoporosis Linked to Endocrine Disorders

An explainable predictive machine learning model of osteopenia for perimenopausal women based on clinical data: a retrospective single-center study

BMI-Adjusted Grip Strength and Sarcopenia in Prediabetes

Researchers report 8% prevalence of probable sarcopenia and a 96.4% specificity cutoff for BMI-adjusted grip strength.